Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

TCBP - TC BioPharm (Holdings) plc

IEX Last Trade
0.72
0.040   5.556%

Share volume: 12,100
Last Updated: Thu 26 Dec 2024 08:28:42 PM CET
Research and Development in Biotechnology (except Nanobiotechnology): -0.11%

PREVIOUS CLOSE
CHG
CHG%
$0.68
0.04
5.88%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
4%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 10%
Performance
5 Days
-0.85%
1 Month
-0.80%
3 Months
-89.26%
6 Months
-20.18%
1 Year
-78.40%
2 Year
-99.92%
Key data
Stock price
$0.72
P/E Ratio 
0.00
DAY RANGE
$0.65 - $0.68
EPS 
$0.00
52 WEEK RANGE
$0.52 - $9.43
52 WEEK CHANGE
-$78.26
MARKET CAP 
2.888 M
YIELD 
N/A
SHARES OUTSTANDING 
518.463 K
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$4,892,590
AVERAGE 30 VOLUME 
$1,934,415
Company detail
CEO: Bryan Kobel
Region: US
Website: tcbiopharm.com
Employees: 80
IPO year: -
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

TC Biopharm (Holdings) Plc focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its products pipeline includes OmnImmune, an unmodified cell therapy used in the treatment of acute myeloid leukemia.

Recent news